Adverse drug reaction reporting in the UK: A retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals

Drug Safety

Volumn 33, Issue 9, 2010, Pages 775-788

  McLernon, David J ^a   Bond, Christine M ^a   Hannaford, Philip C ^a   Watson, Margaret C ^a   Lee, Amanda J ^a   Hazell, Lorna ^b   Avery, Anthony ^c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

adverse reaction monitoring; pharmacovigilance; postmarketing surveillance

Indexed keywords

AMLODIPINE; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; CITALOPRAM; CYPROTERONE; DICLOFENAC; DRUG; ERYTHROMYCIN; ESTROGEN; FLUOXETINE; IBUPROFEN; OLANZAPINE; OMEPRAZOLE; PARACETAMOL; PAROXETINE; RAMIPRIL; RISPERIDONE; SIMVASTATIN; TRAMADOL; TRIMETHOPRIM; VENLAFAXINE;

ABDOMINAL PAIN; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; COMPARATIVE STUDY; CONFUSION; CONNECTIVE TISSUE DISEASE; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG INFORMATION; DRUG SURVEILLANCE PROGRAM; DYSPNEA; ERYTHEMA; EYE DISEASE; FATIGUE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HEALTH CARE PERSONNEL; HEART DISEASE; HEART PALPITATION; HUMAN; INFECTION; INFESTATION; INJURY; KIDNEY DISEASE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OBSERVATIONAL STUDY; PAIN; PATIENT INFORMATION; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN DISEASE; SKIN REDNESS; STOMACH PAIN; SUICIDAL IDEATION; SWEATING; SWELLING; THORAX DISEASE; THORAX PAIN; TREMOR; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE; VASCULAR DISEASE; VOMITING; XEROSTOMIA;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; FEMALE; GREAT BRITAIN; HEALTH PERSONNEL; HUMANS; MALE; MIDDLE AGED; PATIENTS; PHARMACEUTICAL PREPARATIONS; RETROSPECTIVE STUDIES; SEX FACTORS; TIME FACTORS;

EID: 77955570230     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11536510-000000000-00000     Document Type: Article

References (29)

1. Metters J. Report of an independent review of access tothe Yellow Card Scheme. London: The Stationery Office, 2004
2. Van Grootheest K, De Graaf L, De Jong-van Den Berg LTW.Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf 2003; 26 (4): 211-217
3. Blenkinsopp A, Wilkie P, Wang M, et al. Patient reportingof suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol 2006; 63 (2): 148-156
4. Anonymous. UK call for patient ADR reporting. Script 2001; 2634: 4
5. World Health Organisation (WHO). Consumer reporting ofadverse drug reactions. WHO Drug Inf 2000; 14 (4): 211-215
6. Hazell L, Shakir SAW. Under-reporting of adverse drugreactions: a systematic review. Drug Saf 2006; 29 (5): 385-396
7. McGettigan P, Golden J, Conroy RM, et al. Reportingof adverse drug reactions by hospital doctors and the response to intervention. Br J Clin Pharmacol 1997; 44 (1): 98-100
8. Hammond IW, Rich D. Consumers usurp spontaneousadverse event reporting in the United States. Pharmaco-epidemiol Drug Saf 2005; 14: S8-9
9. Health Action International. Patients' reporting of adversereactions: outcomes of a seminar organised by Health Action International Europe, 26 May 2005 [online]. Available from URL: http://www.haiweb.org/docs2005/final-report. doc [Accessed 2010 Feb 23]
10. Aagaard L, Nielsen LH, Hansen EH. Consumer reporting ofadverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Drug Saf 2009; 32 (11): 1067-1074
11. Herxheimer A, Crombag R, Alves TL. Direct patient re-porting of adverse drug reactions: a fifteen-country survey and literature review. HAI briefing paper [online]. Accessed from URL: http://www.haiweb.org/10052010/10- May-2010-Report-Direct-Patient-Reporting-of-ADRs.pdf [Accessed 2010 Jun 30]
12. De Langen J, van Hunsel F, Passier A, et al. Adverse drugreaction reporting by patients in the Netherlands: three years of experience. Drug Saf 2008; 31 (6): 515-524
13. Elkins-Daukes S, Irvine D, Wise L, et al. The Yellow CardScheme: evaluation of patient reporting of suspected adverse drug reactions [abstract]. Pharmacoepidemiol Drug Saf 2006; 15: S105
14. Royal Pharmaceutical Society of Great Britain, BritishMedical Association. British national formulary no. 57. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2009
15. Medicines and Healthcare products Regulatory Agency(MHRA). Download reporting forms and promotional material for the Yellow Card Scheme [online]. Available from URL http://www.mhra.gov.uk/Safetyinformation/ Reportingsafetyproblems/Medicines/Reportingsuspectedadersedrugreactions/ Downloadreportingformsandpromotional material/index.htm [Accessed 2009 Apr 24]
16. Medicines and Healthcare products Regulatory Agency(MHRA). What happens to a yellow card [online]. Available from URL http://www.mhra.gov.uk/ Safetyinformation/ Howwemonitorthesafetyofproducts/Medicines/TheYellow CardScheme/WhathappenstoaYellowCard/index.htm [Accessed 2009 Apr 24]
17. Medicines and Healthcare products Regulatory Agency(MHRA). Evaluation of patient reporting to the yellow card system [online]. Available from URL http://www.mhra.gov.uk/home/idcplg?IdcService=GET-FILE&dDoc Name=CON2023599&RevisionSelectionMethod=Latest [Accessed 2010 Feb 23]
18. House of Commons Health Committee. The influence of thepharmaceutical industry. Fourth report of session 2004-5. London: The Stationery Office, 2005 Apr19. Yellow Card Scheme-MHRA [online]. Accessed fromURL http://yellowcard. mhra.gov.uk// [Accessed 2010 Jun 1]
19. Medicines and Healthcare products Regulatory Agency(MHRA). Patient reporting of suspected adverse drug reactions [online]. Available from URL http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Medi cines/Reportingsuspectedadversedrugreactions/Patientreport ing/index.htm [Accessed 2010 Feb 18]
20. Brown EG, Wood L, Wood S. The medical dictionary forregulatory activities (MedDRA). Drug Saf 1999; 20: 109-117
21. World Health Organisation (WHO). The AnatomicalTherapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD) [online]. Accessed from URL: http://www.who.int/classifications/atcddd/en/ [Accessed 2009 Apr 24]
22. Perry BA, Turner LW. A prediction model for polyphar-macy: are older, educated women more susceptible to an adverse drug event? J Women Aging 2001; 13 (4): 39-51
23. Davies EC, Green CF, Taylor S, et al. Adverse drug reac-tions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE 2009; 4 (2): e4439
24. Zopf Y, Rabe C, Neubert A, et al. Women encounter ADRsmore often than do men. Eur J Clin Pharmacol 2008; 64: 999-1004
25. Egberts TCG, Smulders M, De Koning FHP, et al. Canadverse drug reactions be detected earlier? A comparison of reports by patients and professionals. BMJ 1996; 313: 530-531
26. Foster JM, van Der Molen T, De Jong L-Van Den Berg L.Patient-reporting of side effects may provide an important source of information in clinical practice. Eur J Clin Pharmacol 2007; 63: 979-980
27. Jarernsiripornkul N, Krska J, Richards RME, et al. Patientreporting of adverse drug reactions: useful information for pain management? Eur J Pain 2003; 7: 219-224
28. Basch E. The missing voice of patients in drug-safety re-porting. N Engl J Med 2010; 362: 865-869
29. Waller PC. Making the most of spontaneous adverse drugreaction reporting. Pharmacol Toxicol 2006; 98: 320-323